About this trial
Ascending aortic aneurysms (AAAs) are serious conditions that can lead to aortic dissections or ruptures, carrying a high risk of mortality. Their pathophysiology is based on complex mechanisms involving inflammatory and metabolic processes, as well as alterations in mitochondrial function. The presence of a bicuspid aortic valve (BAV) or tricuspid aortic valve (TAV) significantly influences the progression and severity of aneurysms. Bicuspid aortic valve (BAV) patients often develop aortic aneurysms earlier, as early as age 40-50, whereas tricuspid aortic valve (TAV) patients generally present with a degenerative condition that appears later (after age 50). The objective of this study is to compare the inflammatory, metabolic, and transcriptomic signatures of myeloid cells and total aortic tissue between BAV and TAV patients. These analyses will help identify specific molecular mechanisms, potential biomarkers, and therapeutic targets. To ensure pathophysiological homogeneity, patients with aneurysms of genetic origin (Marfan syndrome, Loeys-Dietz syndrome, Ehlers-Danlos syndrome, etc.) will be excluded.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Individuals who have given their consent
Patients with an ascending aortic aneurysm for which surgical replacement is indicated
Age > 18 years
Scheduled surgery
Disqualifiers
A person subject to a legal protective measure (guardianship, conservatorship)
A person subject to a judicial safeguard measure - A pregnant woman, a woman in labor, or a breastfeeding woman
Adults who are legally incapacitated or unable to give consent
Emergency surgical procedures
Trial population
Patients with ascending aortic aneurysms
Trial design
Cohort
Prospective
Treatments tested in this trial
Additional blood samples
Procedure/SurgeryAdditional blood sample are collected at the time of routine clinical blood sampling for recherche analyses.
Collection of discarded ascending aortic tissue
Procedure/SurgeryThe aneurysmal portion of the ascending aorta (surgical specimen), which would otherwise be discarded, is collected for research purposes. No other tissue is collected, and the research protocol does not alter the surgical procedure.
Treatment groups
Trial outcomes
Primary outcomes
Inflammatory, metabolic, and transcriptomic markers of myeloid cells and aortic tissue
Sponsors and contacts
Click on the lead sponsor to view all of their trials.